Fig. 5

ARF6-KD mice exhibit a delayed, but significant, increase in seizure susceptibility. a Experimental scheme for seizure scoring. The DG region of the hippocampus of ~ 9-week-old WT mice was bilaterally injected with empty AAVs (Control) or ARF6-KD AAVs (ARF6 KD), or co-injected with the following: ARF6-KD AAVs and ARF6-WT–expressing AAVs (ARF6-WT [res.]); ARF6-KD AAVs and ARF6-T27 N–expressing AAVs (ARF6-T27 N [res.]); or ARF6-KD AAVs and ARF6-T157A–expressing AAVs (ARF6-T157A [res.]). Mice were intraperitoneally administered KA 2 weeks after AAV injections, and then analyzed by scoring seizures. b–d Quantification of mean score values for the first 40 min (b), second 40 min (c) and third 40 min (d) under each experimental condition (n = 9 mice/condition; **p < 0.01, ***p < 0.001 vs. control; Kruskal-Wallis test followed by Dunn’s post hoc test). e Quantification of latency to the first seizure after KA administration under each condition (n = 9 mice/condition; **p < 0.01, Kruskal-Wallis test followed by Dunn’s post hoc test). f Quantification of time spent in seizure under each condition (n = 9 mice/condition; **p < 0.01, ***p < 0.001 vs. control; Kruskal-Wallis test followed by Dunn’s post hoc test)